| Nov 5 |
Ultragenyx Pharmaceutical GAAP EPS of -$1.40 beats by $0.08, revenue of $139.45M beats by $4.2M
|
| Nov 5 |
Ultragenyx: Q3 Earnings Snapshot
|
| Nov 5 |
Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update
|
| Nov 4 |
Ultragenyx Pharmaceutical Q3 2024 Earnings Preview
|
| Nov 1 |
What Makes Ultragenyx Pharmaceutical (RARE) an Exciting Investment Opportunity?
|
| Oct 29 |
Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update
|
| Oct 23 |
Recent 4.1% pullback isn't enough to hurt long-term Ultragenyx Pharmaceutical (NASDAQ:RARE) shareholders, they're still up 70% over 1 year
|
| Oct 18 |
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
| Oct 8 |
RARE's Bone Disorder Drug Gets FDA's Breakthrough Therapy Tag
|
| Oct 7 |
Ultragenyx gains Breakthrough Therapy status for setrusumab for genetic disorder
|
